Development of an Insulin Nano-Delivery System through Buccal Administration

Aim: To develop a new nano-delivery system for insulin buccal administration. Background: Biodegradable polymeric nanoparticles (PNPs) had viewed countless breakthroughs in drug delivery systems. The main objective of PNPs application in delivering and carrying different promising drugs is to make sure that the drugs being delivered to their action sites. As a result maximizing the desired effect and overcoming their limitations and drawbacks. Objectives: The main goals of this study were to produce an insulin consumable nano-delivery system for buccal administration and enhance the mucoadhesive effect in sustaining insulin release. Methods: Water in oil in water (W-O-W) microemulsion solvent evaporation technique was used for the preparation of nanoparticles consisting from positively charged poly (D, L-lactide-co-glycolide) coated with chitosan and loaded with insulin. Later, a consumable buccal film was prepared by the spin coating method and loaded with the previously prepared nanoparticles. Results: The newly prepared nanoparticle was assessed in terms of size, charge and surface morphology using a Scanning Electron Microscope (SEM), zeta potential, Atomic Force Microscope (AFM), and Fourier Transform Infra-red (FTIR) spectroscopy. An in-vitro investigation of the insulin release, from nanoparticles and buccal film, demonstrated controlled as well as sustained delivery over 6 hrs. The cumulative insulin release decreased to about (28.9%) with buccal film in comparing with the nanoparticle (50 %). Conclusion: The buccal film added another barrier for insulin release. Therefore, the release was sustained.

Organization and dynamics of the cortical complexes controlling insulin secretion in β-cells

Insulin secretion in pancreatic β-cells is regulated by cortical complexes that are enriched at the sites of adhesion to extracellular matrix facing the vasculature. Many components of these complexes, including Bassoon, RIM, ELKS and liprins, are shared with neuronal synapses. Here, we show that insulin secretion sites also contain non-neuronal proteins LL5β and KANK1, which in migrating cells organize exocytotic machinery in the vicinity of integrin-based adhesions. Depletion of LL5β or focal adhesion disassembly triggered by myosin II inhibition perturbed the clustering of secretory complexes and attenuated the first wave of insulin release. While previous analyses in vitro and in neurons suggested that secretory machinery might assemble through liquid-liquid phase separation, analysis of endogenously labeled ELKS in pancreatic islets indicated that its dynamics is inconsistent with such a scenario. Instead, fluorescence recovery after photobleaching and single molecule imaging showed that ELKS turnover is driven by binding and unbinding to low-mobility scaffolds. Both the scaffold movements and ELKS exchange were stimulated by glucose treatment. Our findings help to explain how integrin-based adhesions control spatial organization of glucose-stimulated insulin release.

Pharmacological Inhibition of NOX4 Improves Mitochondrial Function and Survival in Human Beta-Cells

Previous studies have reported beneficial effects of NADPH oxidase 4 (NOX4) inhibition on beta-cell survival in vitro and in vivo. The mechanisms by which NOX4 inhibition protects insulin producing cells are, however, not known. The aim of the present study was to investigate the effects of a pharmacological NOX4 inhibitor (GLX7013114) on human islet and EndoC-βH1 cell mitochondrial function, and to correlate such effects with survival in islets of different size, activity, and glucose-stimulated insulin release responsiveness. We found that maximal oxygen consumption rates, but not the rates of acidification and proton leak, were increased in islets after acute NOX4 inhibition. In EndoC-βH1 cells, NOX4 inhibition increased the mitochondrial membrane potential, as estimated by JC-1 fluorescence; mitochondrial reactive oxygen species (ROS) production, as estimated by MitoSOX fluorescence; and the ATP/ADP ratio, as assessed by a bioluminescent assay. Moreover, the insulin release from EndoC-βH1 cells at a high glucose concentration increased with NOX4 inhibition. These findings were paralleled by NOX4 inhibition-induced protection against human islet cell death when challenged with high glucose and sodium palmitate. The NOX4 inhibitor protected equally well islets of different size, activity, and glucose responsiveness. We conclude that pharmacological alleviation of NOX4-induced inhibition of beta-cell mitochondria leads to increased, and not decreased, mitochondrial ROS, and this was associated with protection against cell death occurring in different types of heterogeneous islets. Thus, NOX4 inhibition or modulation may be a therapeutic strategy in type 2 diabetes that targets all types of islets.

Different ideas on the pathogenesis and treatment of swine edema-disease

Although literature data associate the reason of swine edema-disease with certain serotypes of Escherichia coli bacteria, the authors assume that the primary cause of edema is more different. Susceptible agents and factors, mostly of feed compound are involved. During the digestion of some feed-origin protein opiate-like metabolites, exorphins arise, simultaneously arrest the release of acetylcholine. Consequences of acetylcholine shortage are spasm of sphincters (mostly pylorus), intestine-dilatation, contraction of bladder-sphincter, and urine retention. The endorphins and exorphins intensify the insulin release from the pancreas, hypoglycemia evolves, which is associated with loss of balance. According to the authors in edema-disease piglet dies because of hypoglycemia.

Molecular mechanisms responsible for the sexual dimorphism in pancreatic β-cell insulin release

In humans, type 2 diabetes mellitus (T2DM) has a higher incidence in males compared to females, a phenotype recapitulated by many rodent models. While the sex difference in insulin sensitivity partially accounts for this phenomenon, hitherto uncharacterized differences in pancreatic β-cell insulin release strongly contribute. Here, we show that stepwise increase in extracellular glucose concentration (2, 5, 7.5, 10, 15, 20 mM) induced electrical activity in β cells of both sexes with similar glucose sensitivity (female, EC50 = 9.45 ± 0.15 mM; male, EC50 = 9.42 ± 0.16 mM). However, female β cells’ resting membrane potential (RMP) and inter-spike potential (IP) were significantly higher compared to males (e.g., at 15 mM glucose: male RMP = −82.7 ± 6.3, IP = −74.3 ± 6.8 mV; female RMP = −50.0 ± 7.1, IP = −41.2 ± 7.3 mV). Females also showed higher frequency of trains of action potential (AP; at 10 mM glucose: male F = 1.13 ± 0.15 trains/min; female F = 1.78 ± 0.25 trains/min) and longer AP-burst duration (e.g., at 10 mM glucose: male, 241 ± 30.8 ms; female, 419 ± 60.2 ms). The higher RMP in females reduced the voltage-gated calcium channel (CaV) availability by ∼60%. This explains the paradoxical observation that, despite identical CaV expression levels and higher electrical activity, the islet Ca2+ transients were smaller in females compared to males. Interestingly, the different RMPs are not caused by altered KATP, TASK, or TALK K+ currents. However, stromatoxin-1–sensitive KV2.1 K+ current amplitude was almost double in males (IK = 130.93 ± 7.05 pA/pF) compared to females (IK = 75.85 ± 11.3 pA/pF) when measured at +80 mV. Our results are in agreement with previous findings showing that KV2.1 genetic deletion or pharmacological block leads to higher insulin release and β-cell survival. Therefore, we propose the sex-specific expression of KV2.1 to be the mechanism underlying the observed sexual dimorphism in insulin release and the incidence of T2DM.

CaV1.3 L-type Ca2+ channel modulates pancreatic β-cell electrical activity and survival

Pancreatic β cells express several high voltage-gated Ca2+ channel (HVCC) isoforms critical for insulin release, cell differentiation, and survival. RNaseq and qPCR analyses demonstrated that CACNA1D gene encoding for CaV1.3-α1D isoform is highly expressed in pancreatic islets of both mice and men. Additionally, CACNA1D genetic polymorphisms were associated with increased susceptibility for diabetes while CaV1.3 gain-of-function mutations cause hyperinsulinemia in humans. Nevertheless, functional evidence for the role of CaV1.3 on β-cell electrical activity, insulin release, and β-cell mass is contradictory and largely unknown. Here, we show that CaV1.3 deletion led to a sixfold increase in DNA damage and a threefold decrease in proliferation markers in pancreatic β cells of 14-d-old mice, while adult mice were largely unaffected. However, β-cell mass was reduced by ∼20% in both young and old mice, resulting in a diminished sustained insulin release. Voltage-clamp recordings in β-cells of 14-d-old mice showed an ∼20% reduction in total Ca2+ influx (WT Ipeak = −19.76 ± 1.04 pA/pF; CaV1.3−/− Ipeak = −14.84 ± 0.61 pA/pF, P = 0.001) accompanied by slower inactivation and an ∼5 mV rightwards shift in the voltage dependence of activation (WT V1/2 = −7.71 ± 0.82 mV; CaV1.3−/− V1/2 = −2.32 ± 1.09 mV, P = 0.0003). Although to a lower extent, Ca2+ influx in adult CaV1.3−/− β cells was similarly affected. Moreover, current-clamp recordings showed that CaV1.3 deletion delayed the glucose-induced action potential (AP) onset, reduced AP firing frequency (e.g., at 7.5 mM glucose, WT = 4.3 Hz; CaV1.3−/− = 2.1 Hz, P = 0.001) and AP-train frequency (e.g., at 7.5 mM glucose intertrain interval, WT = 49.3 ± 9.6 s; CaV1.3−/− = 120.3 ± 25.5 s, P = 0.04) in both young and adult β cells. Therefore, our data demonstrate that the CaV1.3 channel is required for the initiation of glucose-induced β-cell electrical activity and modulates β-cell mass and insulin release in both young and old mice.